Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.49 |
| ▸ | WIZ | O95785 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21982887 | 0.92 | CRBN (0.57) | IKZF2CRBNDDB1WIZCSNK1A1 | |
| SCHEMBL20234936 | 0.84 | IKZF2 (0.54) | IKZF2CRBNWIZ | |
| SCHEMBL30720192 | 0.84 | CRBN (0.56) | IKZF2CRBNDDB1WIZCSNK1A1 | |
| SCHEMBL29547522 | 0.84 | CRBN (0.56) | IKZF2CRBNDDB1WIZCSNK1A1 | |
| SCHEMBL27301548 | 0.84 | CRBN (0.56) | IKZF2CRBNDDB1WIZCSNK1A1 | |
| SCHEMBL30720169 | 0.84 | CRBN (0.56) | IKZF2CRBNDDB1WIZCSNK1A1 | |
| SCHEMBL20046704 | 0.84 | CRBN (0.56) | IKZF2CRBNDDB1WIZCSNK1A1 | |
| SCHEMBL31611548 | 0.84 | CRBN (0.56) | IKZF2CRBNDDB1WIZCSNK1A1 | |
| SCHEMBL22536268 | 0.83 | WIZ (0.53) | IKZF2CRBNWIZCSNK1A1 | |
| SCHEMBL19586965 | 0.82 | CRBN (0.56) | IKZF2CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | IKZF2 1564/4885CRBN 2/4885DDB1 192/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | IKZF2 1564/4885CRBN 2/4885DDB1 192/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | IKZF2 1564/4885CRBN 2/4885DDB1 192/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | IKZF2 1564/4885CRBN 2/4885DDB1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.